Sökning: WFRF:(Maitland van der Zee Anke Hilse) >
Cost-effectiveness ...
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
-
- Verhoef, Talitha I (författare)
- University of Utrecht, Netherlands
-
- Redekop, William K (författare)
- Erasmus University, Netherlands
-
- van Schie, Rianne M F (författare)
- University of Utrecht, Netherlands
-
visa fler...
-
- Bayat, Samira (författare)
- University of Utrecht, Netherlands
-
- Daly, Ann K (författare)
- Newcastle University, England
-
- Geitona, Mary (författare)
- University of Peloponnese, Greece
-
- Haschke-Becher, Elisabeth (författare)
- Elisabethinen Hospital Linz, Austria
-
- Hughes, Dyfrig A (författare)
- Bangor University, Wales
-
- Kamali, Farhad (författare)
- Newcastle University, England
-
- Levin, Lars-Åke (författare)
- Linköpings universitet,Utvärdering och hälsoekonomi,Hälsouniversitetet
-
- Manolopoulos, Vangelis G (författare)
- Democritus University of Thrace, Greece
-
- Pirmohamed, Munir (författare)
- University of Liverpool, England
-
- Siebert, Uwe (författare)
- Harvard University, MA USA Harvard University, MA 02115 USA ONCOTYROL Centre Personalized Cancer Med, Austria UMIT University of Health Science Medical Informat and Technology, Austria UMIT University of Health Science Medical Informat and Technology, Austria
-
- Stingl, Julia C (författare)
- University of Ulm, Germany
-
- Wadelius, Mia (författare)
- Uppsala universitet,Klinisk farmakologi,Uppsala University, Sweden
-
- de Boer, Anthonius (författare)
- University of Utrecht, Netherlands
-
- Maitland-van der Zee, Anke-Hilse (författare)
- University of Utrecht, Netherlands
-
visa färre...
-
(creator_code:org_t)
- Future Medicine, 2012
- 2012
- Engelska.
-
Ingår i: Pharmacogenomics (London). - : Future Medicine. - 1462-2416 .- 1744-8042. ; 13:12, s. 1405-1417
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.2...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy of dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin derivatives). The anticipated degree of improvement in the safety of anticoagulation with coumarins through genotyping may vary depending on the quality of patient care, which varies both with and among countries. The management and the cost of anticoagulant care can therefore influence the cost effectiveness of genotyping within any given country. In this article, we provide an overview of the cost effectiveness of pharmacogenetics-guided dosing of coumarin derivatives. We describe the organization of anticoagulant care in the UK, Sweden, The Netherlands, Greece, Germany and Austria, where a genotype-guided dosing algorithm is currently being investigated as part of the EU-PACT trial. We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries.
Nyckelord
- acenocoumarol
- atrial fibrillation
- cost analysis
- coumarins
- health
- economics
- healthcare system
- phenprocoumon
- warfarin
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Verhoef, Talitha ...
-
Redekop, William ...
-
van Schie, Riann ...
-
Bayat, Samira
-
Daly, Ann K
-
Geitona, Mary
-
visa fler...
-
Haschke-Becher, ...
-
Hughes, Dyfrig A
-
Kamali, Farhad
-
Levin, Lars-Åke
-
Manolopoulos, Va ...
-
Pirmohamed, Muni ...
-
Siebert, Uwe
-
Stingl, Julia C
-
Wadelius, Mia
-
de Boer, Anthoni ...
-
Maitland-van der ...
-
visa färre...
- Artiklar i publikationen
-
Pharmacogenomics ...
- Av lärosätet
-
Linköpings universitet
-
Uppsala universitet